Cumberland Pharmaceuticals Files 8-K on Financials
Ticker: CPIX · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1087294
Sentiment: neutral
Topics: financial-results, sec-filing
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K on Nov 4, 2025, detailing financial results. Check it out.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on November 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to this information. The company is incorporated in Tennessee and its principal executive offices are located in Nashville.
Why It Matters
This 8-K filing provides an update on Cumberland Pharmaceuticals' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC (company) — Registrant
- November 4, 2025 (date) — Date of Report
- Tennessee (location) — State of Incorporation
- Nashville (location) — Principal Executive Offices City
- 615-255-0068 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on November 4, 2025.
Where is Cumberland Pharmaceuticals Inc. headquartered?
The company's principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is Cumberland Pharmaceuticals Inc.'s state of incorporation?
The company is incorporated in Tennessee.
What is the SIC code for Cumberland Pharmaceuticals Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-11-04 17:11:16
Filing Documents
- cpix-20251104.htm (8-K) — 28KB
- a2025q3-ex991er.htm (EX-99.1) — 247KB
- image_0.jpg (GRAPHIC) — 19KB
- 0001087294-25-000017.txt ( ) — 439KB
- cpix-20251104.xsd (EX-101.SCH) — 2KB
- cpix-20251104_lab.xml (EX-101.LAB) — 21KB
- cpix-20251104_pre.xml (EX-101.PRE) — 12KB
- cpix-20251104_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 4, 2025 , Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release dated November 4 , 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: November 4, 2025 By: /s/ John Hamm John Hamm Chief Financial Officer